Molecular mechanisms in the antiproliferative action of taxol and tiazofurin

Related Experiment Video

Updated: Aug 13, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

E Olah1, B Csokay, N Prajda

  • 1National Institute of Oncology, Budapest, Hungary.

Anticancer Research
|September 1, 1996
PubMed

Insights

Taxol and tiazofurin induce differentiation and apoptosis in leukemia and carcinoma cells. Combined treatment shows synergistic antiproliferative effects, particularly when tiazofurin precedes taxol.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer cell proliferation is a hallmark of malignancy.
  • Taxol and tiazofurin are known cytotoxic agents with distinct mechanisms.
  • Understanding their combined effects is crucial for novel therapeutic strategies.

Purpose of the Study:

  • To investigate the molecular antiproliferative effects of taxol and tiazofurin.
  • To evaluate the combined effects of taxol and tiazofurin on cancer cell lines.
  • To determine the optimal treatment schedule for synergistic antiproliferative activity.

Main Methods:

  • Treatment of K562 leukemia, MCF-7 breast, and OVCAR-5 ovarian carcinoma cell lines with taxol and/or tiazofurin.
  • Assessment of cell differentiation and apoptosis.
  • Measurement of IMP dehydrogenase activity.
  • Analysis of c-myc and Ki-ras oncogene expression.
  • Evaluation of GTP levels.

Main Results:

  • Both taxol and tiazofurin induced differentiation and apoptosis in K562 cells.
  • Tiazofurin was a potent inducer of differentiation, while taxol strongly induced apoptosis.
  • Tiazofurin inhibited IMP dehydrogenase activity, dependent on GTP supply.
  • Both agents downregulated c-myc and Ki-ras oncogenes.
  • Combined treatment demonstrated schedule-dependent synergistic antiproliferative effects, with tiazofurin pretreatment enhancing taxol efficacy.

Conclusions:

  • Taxol and tiazofurin exhibit distinct yet complementary antiproliferative mechanisms.
  • Combined therapy with a specific schedule can achieve synergistic cancer cell death.
  • Targeting IMP dehydrogenase and oncogene expression are key molecular events.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...